Mycophenolate mofetil showed no clear difference in overall survival compared with methotrexate (low certainty).
It is very uncertain whether mycophenolate mofetil changes prevention of acute GVHD grade II to IV compared with methotrexate (very low certainty).
Mycophenolate mofetil showed no clear difference in incidence of relapse compared with methotrexate (low certainty).
Mycophenolate mofetil showed no clear difference in nonrelapse mortality compared with methotrexate (low certainty).
Mycophenolate mofetil showed no clear difference in prevention of chronic GVHD compared with methotrexate (low certainty).
Mycophenolate mofetil may leads to lower incidence of severe mucositis compared with methotrexate (low certainty).
Mycophenolate mofetil may leads to lower use of total parenteral nutrition compared with methotrexate (low certainty).
Mycophenolate mofetil may leads to lower incidence of narcotic use for pain control compared with methotrexate (low certainty).
Mycophenolate mofetil showed no clear difference in frequent relapses at 12 months compared with levamisole (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether mycophenolate mofetil changes adverse effects: peritonitis compared with levamisole (very low certainty).
Mycophenolate mofetil showed no clear difference in adverse effects: abdominal pain compared with levamisole (low certainty).
It is very uncertain whether mycophenolate mofetil changes adverse effects: anaemia compared with levamisole (very low certainty).
It is very uncertain whether mycophenolate mofetil changes adverse effects: leukopenia compared with levamisole (very low certainty).
Mycophenolate mofetil showed no clear difference in relapse at 12 months compared with cyclosporin (low certainty).
The review found no eligible studies for this question.
Mycophenolate mofetil showed no clear difference in adverse effects: hypertension compared with cyclosporin (low certainty).
Mycophenolate mofetil may leads to lower adverse effects: hypertrichosis compared with cyclosporin (low certainty).
Mycophenolate mofetil showed no clear difference in adverse effects: lymphopenia compared with cyclosporin (low certainty).
The findings closest to your search, judged one by one by TypeSafe's Jev model.